ARTICLE | Company News
Medarex other research news
October 10, 1994 7:00 AM UTC
MEDX received a CaP CURE foundation grant for an undisclosed sum to conduct a Phase I/II trial of its MDX-210 Bispecific antibody therapy for prostate cancer. MEDX (Princeton, N.J.) said the trial is ...